The role of compounding in closing therapeutic gaps (Parts 1 and 2)
Thursday 5th of September 2013
09:00-17:00
C9, 6 hours
Organised by the FIP Community Pharmacy Section, the FIP Hospital Pharmacy Section (TBC), the FIP Laboratories and Medicines Control Services (TBC) and the FIP Special Interest Groups on Formulation Design and Pharmaceutical Technology , and on Translational Research
Introduction
Introduction
Compounding is a service that has again been increasingly adopted by pharmacists over the last three decades. Researchers at the University of Sydney have identified some of the motives of these pharmacists as: a strategy for reprofessionalisation; professional satisfaction; demand by patients and doctors for customised medications; and financial returns that are in line with a professional service. Compounding today is not the same as 50 years ago. Pharmacists now have access to a huge range of ingredients, compounding equipment and dosage forms, and are able to help patients and doctors solve medication problems that many have given up trying to fix. The emphasis on solving medication problems has moved compounding from a product focused activity to one in which the compounding pharmacist is a hugely valuable member of the patient’s healthcare team.
Learning objectives
Learning objectives
At the conclusion of the session, participants will be able to:
- Describe how to manage and implement GMP in the pharmacy setting
- Describe how to guarantee the quality of the product in small scale production
- Portray and understand the role of compounding in paediatric medicines
- Portray and understand the role of compounding in oncology
- Portray and understand the role of compounding in dermatology.
- Describe how to manage and implement GMP in the pharmacy setting
- Describe how to guarantee the quality of the product in small scale production
- Portray and understand the role of compounding in paediatric medicines
- Portray and understand the role of compounding in oncology
- Portray and understand the role of compounding in dermatology.
Chair: Eugene Lutz (FIP CPS, USA)
Programme
1) Biopharmaceutical principles of compoundingGiovanni Pauletti (University of Cincinnati, USA)
2) When NOT to compound and consideration before compoundingMaria Carvalho (Portugal)
Break
3) Guidelines and standards in compounding Gigi Davidson (USP Compounding Expert Committee 2010-’15, USA)
4) Quality assurance inpharmacy compounding /preparationHolger Reimann (Germany)
Break
5) Compounding of pediatric medicinesLisa Ashworth (Children’s Medical Center of Dallas TX, USA)
6) Sterile compounding Vaiyapuri Subramaniam (Veterans Health Administration, USA)
Break
7) Compounding in dermatology Francesc Llambi (APROFARM – COF Barcelona, Spain)
2) When NOT to compound and consideration before compoundingMaria Carvalho (Portugal)
Break
3) Guidelines and standards in compounding Gigi Davidson (USP Compounding Expert Committee 2010-’15, USA)
4) Quality assurance in
Break
5) Compounding of pediatric medicinesLisa Ashworth (Children’s Medical Center of Dallas TX, USA)
6) Sterile compounding Vaiyapuri Subramaniam (Veterans Health Administration, USA)
Break
7) Compounding in dermatology Francesc Llambi (APROFARM – COF Barcelona, Spain)
No comments:
Post a Comment